Recurrent Clostridium difficile infection and the microbiome

Journal of Gastroenterology

Volumn 51, Issue 1, 2016, Pages 1-10

  Almeida, Rowena ^a   Gerbaba, Teklu ^a   Petrof, Elaine O ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Clostridium difficile; Fecal microbiota transplantation; Microbiome

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT;

BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE TRANSMISSION; DRUG REEXPOSURE; ENVIRONMENTAL FACTOR; FECAL MICROBIOTA TRANSPLANTATION; FECES INCONTINENCE; HUMAN; HYPOALBUMINEMIA; ILEUM POUCH; INTESTINE FLORA; MICROBIAL ECOSYSTEM THERAPEUTIC; NONHUMAN; PATIENT SAFETY; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; RISK FACTOR; ADVERSE EFFECTS; COMPLICATION; DYSBIOSIS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; MICROBIOLOGY; PROCEDURES; RECURRENT DISEASE;

CLOSTRIDIUM DIFFICILE; DYSBIOSIS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HUMANS; RECURRENCE; RISK FACTORS;

EID: 84953348832     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-015-1099-3     Document Type: Review

References (100)

1. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65.
2. Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology. 2014;146(6):1449–58.
3. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S12–8.
4. George RH, Symonds JM, Dimock F, et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J. 1978;1(6114):695.
5. Kelly CP, LaMont JT. Clostridium difficile–more difficult than ever. N Engl J Med. 2008;359(18):1932–40.
6. Hall I, O’Toole E. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe. Bacillus difficilis. 1935;49:390–402.
7. Kwon JH, Olsen MA, Dubberke ER. The morbidity, mortality, and costs associated with Clostridium difficile infection. Infect Dis Clin North Am. 2015;29(1):123–34.
8. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55(Suppl 2):S88–92.
9. Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut liver. 2014;8(1):1–6.
10. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev. 2010;23(3):529–49.
11. He M, Miyajima F, Roberts P, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet. 2013;45(1):109–13.
12. Khanna S, Pardi DS, Aronson SL, et al. Outcomes in community-acquired Clostridium difficile infection. Aliment Pharmacol Ther. 2012;35(5):613–8.
13. Centers for Disease Control and Prevention. (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk-four states. MMWR Morb Mortal Wkly Rep. 2005;54(47):1201–5.
14. Chitnis AS, Holzbauer SM, Belflower RM, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med. 2013;173(14):1359–67.
15. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol. 2011;8(1):17–26.
16. Wilcox MH, Mooney L, Bendall R, et al. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother. 2008;62(2):388–96.
17. Bolton RP, Tait SK, Dear PR, et al. Asymptomatic neonatal colonisation by Clostridium difficile. Arch Dis Child. 1984;59(5):466–72.
18. Tullus K, Aronsson B, Marcus S, et al. Intestinal colonization with Clostridium difficile in infants up to 18 months of age. Eur J Clin Microbiol Infect Dis. 1989;8(5):390–3.
19. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec. Canada Clin Infect Dis. 2005;40(11):1591–7.
20. Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents. 2009;33(Suppl 1):S33–6.
21. Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377(9759):63–73.
22. Garey KW, Dao-Tran TK, Jiang ZD, et al. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect. 2008;70(2):142–7.
23. Pépin J, Routhier S, Gagnon S, et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec. Canada Clin Infect Dis. 2006;42(6):758–64.
24. Eyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis. 2012;55(Suppl 2):S77–87.
25. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 2009;136(4):1206–14.
26. Cohen MB. Clostridium difficile infections: emerging epidemiology and new treatments. J Pediatr Gastroenterol Nutr. 2009;48(Suppl 2):S63–5.
27. Kelsen JR, Kim J, Latta D, et al. Recurrence rate of Clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(1):50–5.
28. Rupnik M. Is Clostridium difficile-associated infection a potentially zoonotic and foodborne disease? Clin Microbiol Infect. 2007;13(5):457–9.
29. Keel K, Brazier JS, Post KW, et al. Prevalence of PCR ribotypes among Clostridium difficile isolates from pigs, calves, and other species. J Clin Microbiol. 2007;45(6):1963–4.
30. Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe. 2009;15(6):285–9.
31. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol. 2005;54(Pt 2):101–11.
32. Allen-Vercoe E, Reid G, Viner N, et al. A Canadian working group report on fecal microbial therapy: microbial ecosystems therapeutics. Can J Gastroenterol. 2012;26(7):457–62.
33. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197(3):435–8.
34. Kong LY, Dendukuri N, Schiller I, et al. Predictors of asymptomatic Clostridium difficile colonization on hospital admission. Am J Infect Control. 2015;43(3):248–53.
35. Alasmari F, Seiler SM, Hink T, et al. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis. 2014;59(2):216–22.
36. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837–48.
37. Rousseau C, Poilane I, De Pontual L, et al. Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin Infect Dis. 2012;55(9):1209–15.
38. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4554–61.
39. Merrigan M, Sambol S, Johnson S, et al. Susceptibility of hamsters to human pathogenic Clostridium difficile strain B1 following clindamycin, ampicillin or ceftriaxone administration. Anaerobe. 2003;9(2):91–5.
40. Sambol SP, Merrigan MM, Tang JK, et al. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis. 2002;186(12):1781–9.
41. Vincent C, Stephens DA, Loo VG, et al. Reductions in intestinal clostridiales precede the development of nosocomial Clostridium difficile infection. Microbiome. 2013;1(1):18.
42. Wilson KH. The microecology of Clostridium difficile. Clin Infect Dis. 1993;16(Suppl 4):S214–8.
43. Gerber GK. The dynamic microbiome. FEBS Lett. 2014;588(22):4131–9.
44. Caporaso JG, Lauber CL, Costello EK, et al. Moving pictures of the human microbiome. Genome Biol. 2011;12(5):R50.
45. McDonald EG, Milligan J, Frenette C, et al. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med. 2015;5(175):784–91.
46. Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis. 1997;24(3):324–33.
47. Garey KW, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70(4):298–304.
48. Cadena J, Thompson GR, Patterson JE, et al. Clinical predictors and risk factors for relapsing Clostridium difficile infection. Am J Med Sci. 2010;339(4):350–5.
49. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357(9251):189–93.
50. Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2010;28(4):965–9.
51. Petrella LA, Sambol SP, Cheknis A, et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis. 2012;55(3):351–7.
52. Seril DN, Ashburn JH, Lian L, et al. Risk factors and management of refractory or recurrent Clostridium difficile infection in ileal pouch patients. Inflamm Bowel Dis. 2014;20(12):2226–33.
53. Tal S, Gurevich A, Guller V, et al. Risk factors for recurrence of Clostridium difficile-associated diarrhea in the elderly. Scand J Infect Dis. 2002;34(8):594–7.
54. Rotramel A, Poritz LS, Messaris E, et al. PPI therapy and albumin are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics. J Gastrointest Surg. 2012;16(12):2267–73.
55. Kim JW, Lee KL, Jeong JB, et al. Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol. 2010;16(28):3573–7.
56. Nicholson MR, Thomsen IP, Slaughter JC, et al. Novel risk factors for recurrent Clostridium difficile infection in children. J Pediatr Gastroenterol Nutr. 2015;60(1):18–22.
57. Deshpande A, Pasupuleti V, Thota P, et al. Risk factors for recurrent Clostridium difficile Infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36(4):452–60.
58. Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772–8.
59. Freedberg DE, Salmasian H, Friedman C, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol. 2013;108(11):1794–801.
60. Amir I, Konikoff FM, Oppenheim M, et al. Gastric microbiota is altered in oesophagitis and Barrett’s oesophagus and further modified by proton pump inhibitors. Environ Microbiol. 2014;16(9):2905–14.
61. Seto CT, Jeraldo P, Orenstein R, et al. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014;2:42.
62. Bollinger RR, Barbas AS, Bush EL, et al. Biofilms in the normal human large bowel: fact rather than fiction. Gut. 2007;56(10):1481–2.
63. Guinane CM, Tadrous A, Fouhy F, et al. Microbial composition of human appendices from patients following appendectomy. MBio. 2013;4(1):e00366–12. http://mbio.asm.org/content/4/1/e00366-12.
64. Im GY, Modayil RJ, Lin CT, et al. The appendix may protect against Clostridium difficile recurrence. Clin Gastroenterol Hepatol. 2011;9(12):1072–7.
65. Zhang F, Luo W, Shi Y, et al. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol. 2012;11(107):1755 (author reply p-6).
66. Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44(5):854–9.
67. Schwan A, Sjölin S, Trottestam U, et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet. 1983;2(8354):845.
68. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53(10):994–1002.
69. Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500–8.
70. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48(8):693–702.
71. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–15.
72. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58(11):1515–22.
73. ClinicalTrials.gov. Search of “Clostridium difficile” and “fecal microbiota transplantation” studies 2015. https://clinicaltrials.gov/ct2/resultsterm=%22Clostridium+difficile%22+AND+%22fecal+microbiota+transplantation%22&Search=Search. Accessed 1 June 2015.
74. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044–9.
75. Moayyedi P, Marshall JK, Yuan Y, et al. Canadian association of gastroenterology position statement: fecal microbiota transplant therapy. Can J Gastroenterol Hepatol. 2014;28(2):66–8.
76. Merenstein D, El-Nachef N, Lynch SV. Fecal microbial therapy: promises and pitfalls. J Pediatr Gastroenterol Nutr. 2014;59(2):157–61.
77. Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol. 2010;8(5):471–3.
78. FDA Draft guidance for industry: enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. US. Department of Health and Human Services, Food and Drug Administration 2014. http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm387023.htm. Accessed 7 May 2015.
79. HealthCanada. Health Canada Guidance Document. Regulation of Fecal Microbiota Therapy for the treatment of C. difficile Infections 2015. http://www.hc-sc.gc.ca/dhp-mps/consultation/biolog/fecal_microbiota-bacterio_fecale-eng.php. Accessed 7 May 2015.
80. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107(7):1079–87.
81. Solari PR, Fairchild PG, Noa LJ, et al. Tempered enthusiasm for fecal transplant. Clin Infect Dis. 2014;59(2):319.
82. Kling J Fecal Transplant an option even in the immunocompromised. October 16 2013. http://www.medscape.com/viewarticle/812685. Accessed 5 May 2015.
83. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109(7):1065–71.
84. Angelberger S, Reinisch W, Makristathis A, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol. 2013;108(10):1620–30.
85. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11(8):1036–8.
86. Kump PK, Gröchenig HP, Lackner S, et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis. 2013;19(10):2155–65.
87. Hamilton MJ, Weingarden AR, Unno T, et al. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes. 2013;4(2):125–35.
88. Shankar V, Hamilton MJ, Khoruts A, et al. Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. Microbiome. 2014;2:13.
89. Khoruts A, Sadowsky MJ, Hamilton MJ. Development of fecal microbiota transplantation suitable for mainstream medicine. Clin Gastroenterol Hepatol. 2015;13(2):246–50.
90. Hamilton MJ, Weingarden AR, Sadowsky MJ, et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107(5):761–7.
91. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312(17):1772–8.
92. Rao K, Young VB. Fecal microbiota transplantation for the management of Clostridium difficile infection. Infect Dis Clin North Am. 2015;29(1):109–22.
93. Khoruts A, Dicksved J, Jansson JK, et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010;44(5):354–60.
94. Buffie CG, Bucci V, Stein RR, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205–8.
95. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1(8648):1156–60.
96. Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome. 2013;1(1):3.
97. Rupnik M. Toward a true bacteriotherapy for Clostridium difficile infection. N Engl J Med. 2015;372(16):1566–8.
98. Lawley TD, Clare S, Walker AW, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 2012;8(10):e1002995.
99. Petrof EO, Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology. 2014;146(6):1573–82.
100. Petrof EO, Claud EC, Gloor GB, et al. Microbial ecosystems therapeutics: a new paradigm in medicine? Benef Microbes. 2013;4(1):53–65.